KGKevin Gregory-Evans

Kevin Gregory-Evans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin Gregory-Evans has a total of 173 co-authors. Here are the top co-authors by number of shared publications:

  • Cheryl Y. Gregory-Evans

    Department of Ophthalmology and Visual Sciences, University of British Columbia, Canada

    21 shared publications
  • Cheryl Y. Gregory-Evans

    University of British Columbia

    13 shared publications
  • Anat Yanai

    Department of Ophthalmology and Visual Sciences Eye, Care Centre University of British Columbia Vancouver Canada

    9 shared publications
  • Ishaq A. Viringipurampeer

    Department of Ophthalmology and Visual Sciences Eye, Care Centre University of British Columbia Vancouver Canada

    8 shared publications
  • Abu Emran Bashar

    Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow Street, Vancouver, BC, V5Z 3N9, Canada

    6 shared publications
  • Andrew L. Metcalfe

    Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow Street, Vancouver, BC, V5Z 3N9, Canada

    5 shared publications

Latest Publications

  • Open Access

    Two novel genetic associations with sector retinitis pigmentosa: USH2A and PRPF31

    by Shanil R. Dhanji, Kirk A. J. Stephenson, Cheryl Y. Gregory-Evans, Kevin Gregory-Evans

    Sector retinitis pigmentosa (RP) is an attenuated phenotype in comparison to classic pan-retinal disease. The inferior retina is most often affected, though other quadrants may become involved with time, particularly with more damaging genetic variants. Sector RP has been described in association with several known genotypes, most commonly RHO. Case series of patients with a sector RP phenotype (and any affected family) and review of the literature. We describe two new genetic associations of sector RP: USH2A and PRPF31. Proband 1 had sector RP due to homozygous USH2A:c.13274C>T' variants while proband 2 had sector RP due to a heterozygous PRPF31:c.351dup variant. There was significant intrafamilial variability in each pedigree. Though both variants are previously reported, the phenotype in those reports was not consistent with sector RP. The current USH2A pedigree is the first reported with the c.13274C>T' variant homozygously, expressing a restricted, predominantly perivascular, sectoral RP. Non-syndromic USH2 genes have not previously been associated with sector RP. In the PRPF31 pedigree (c.351dup), the proband has restricted/sectoral disease but her daughter has classic pan-retinal RP. The cause of the attenuated phenotype and intrafamilial variability is unknown but could depend on several factors including occult modifier genes and environmental influences (e.g. light exposure to the inferior retina).


  • Open Access

    Expanding the Genotypic Landscape of Congenital Stationary Night Blindness in an Ethnically Diverse Canadian Population

    by Jennifer Ling, Mustansir Pindwarawala, Cheryl Y. Gregory-Evans, Mathew Kirby, Kevin Gregory-Evans

    Congenital stationary night blindness (CSNB) is a rare and typically nonprogressive group of genetically heterogeneous disorders resulting in impaired night vision and high myopia with varying levels of visual impairment. Despite being a rare disease with a prevalence of 1:294,000, variants in 22 genes have been associated with specific CSNB phenotypes. Approximately, 13% of cases remain without a genetic diagnosis, highlighting the importance of ongoing genetic studies. Clinical and diagnostic information was collected retrospectively from patients who were diagnosed with CSNB. Patients underwent full ophthalmic examination, including best‐corrected visual acuity (BCVA), direct and indirect ophthalmoscopy, retinal imaging, and full field electroretinography. All patients underwent panel‐based genetic testing for complete and incomplete CSNB genes to identify DNA variants from buccal swab samples. In the 49‐patient cohort (from 38 families) with complete and incomplete CSNB, a conclusive molecular diagnosis was found in 30 patients (61.2%) with a known disease‐causing variant in a CSNB gene. We identified 21 novel variants in five genes ( CACNA1F , NYX , TRPM1 , GPR 197, and GRK1 ), and in one patient, the genetic defect remains to be identified. After in silico modeling and clinical correlation, 18 of these novel variants were considered pathogenic or likely pathogenic. When compared with ethnicity, CSNB was overwhelmingly present in White people, and we did not find any Indigenous people with CSNB. Prevalence of CSNB in the Mennonite community was estimated to be 1:967, approximately 300 times the expected prevalence. Establishing a molecular diagnosis of CSNB is critical because it enables many actionable outcomes including further family testing, genetic counseling, and access to future clinical trials.

  • Open Access

    RPE65 variant p.(E519K) causes a novel dominant adult-onset maculopathy in 83 affected individuals

    by Eline Van Vooren, Filip Van Den Broeck, Quinten Mahieu, Eline Geens, Mattias Van Heetvelde, Marieke De Bruyne, Stijn Van de Sompele, Sheetal Uppal, Eugenia Poliakov, Claire-Marie Dhaenens, et al.

    Recessive RPE65-related retinopathy is an inherited retinal disease (IRD) that is a well-established target for gene therapy. Dominant RPE65-related retinopathy, however, due to Irish founder variant p.(D477G), is extremely rare. Here, we report the discovery, replication and characterization of a novel dominant retinopathy caused by RPE65 variant p.(E519K), identified in 83 individuals of European ancestry across IRD registries (Belgian discovery cohort, n=2,873; replication cohort, n=18,796). Long-read sequencing-based haplotyping revealed a shared region of 464 kb, supporting a founder effect. Genotype-phenotype data support dominant inheritance and phenotypic variability respectively, characterized by late-onset macular dystrophy with two main subtypes, a pathognomonic mottled subtype and a pattern dystrophy subtype. Functional studies showed that the p.(E519K) variant affects RPE65 enzymatic activity, correlating with lower protein expression. Protein modelling and cellular thermal shift assays further supported a destabilizing effect on protein structure. Overall, our work provides strong genetic, clinical, molecular and functional evidence for a novel dominant RPE65 retinopathy in multiple families in Europe and North America due to a Belgian founder variant. This discovery reduces the diagnostic gap in dominant IRD, particularly in individuals of European ancestry. Finally, it lays the foundation for developing therapeutic strategies targeting dominant RPE65 retinopathy.


    • 15 December 2023
      • Vol. 29, 329-337
    Open Access

    Novel pathogenic variants in Tubulin Tyrosine Like 5 (TTLL5) associated with cone-dominant retinal dystrophies and an abnormal optical coherence tomography phenotype.

    by Olubayo U. Kolawole, Cheryl Y. Gregory-Evans, Riyaz Bikoo, Albert Z. Huang, Kevin Gregory-Evans

    Autosomal recessive cone and cone-rod dystrophies (CD/CRD) are inherited forms of vison loss. Here, we report on and correlate the clinical phenotypes with the underlying genetic mutations. Clinical information was collected from subjects, including a family history with a chart review. They underwent a full ophthalmic examination, including best-corrected visual acuity, direct and indirect ophthalmoscopy, color vision testing, color fundus photography, contrast sensitivity, autofluorescence, and spectral domain-optical coherence tomography (SD-OCT), and full-field electroretinography. Next-generation panel-based genetic testing was used to identify DNA variants in subject buccal swab samples. Genetic testing in two patients revealed three novel variants in the TTLL5 gene associated with CD/CRD: two missense variants (c.1433G>A;p.(Arg478Gln), c.241C>G;p.(Leu81Val), and one loss-of-function variant (c.2384_2387del;p.(Ala795Valfs*9). Based on in-silico analysis, structural modeling, and comparison to previously reported mutations, these novel variants are very likely to be disease-causing mutations. Combining retinal imaging with SD-OCT analysis, we observed an unusual sheen in the CD/CRD phenotypes. Based on the protein domain location of novel TTLL5 variants and the localization of TTLL5 to the connecting cilium, we conclude that the CD/CRD disease phenotype is characterized as a ciliopathy caused by protein tracking dysfunction. This initially affects cone photoreceptors, where photoreceptor cilia express a high level of TTLL5, but extends to rod photoreceptors over time. Fundus photography correlated with SD-OCT imaging suggests that the macular sheen characteristically seen with TTLL5 mutations derives from the photoreceptor's outer segments at the posterior pole.


  • Molecular genetic diagnostics for inherited retinal dystrophies in the clinical setting

    by Olubayo U. Kolawole, Albert Huang, Cheryl Y. Gregory-Evans, Maheshver Shunmugam, Travers Weaver, Kevin Gregory-Evans


  • Photoreceptor precursor cell integration into rodent retina after treatment with novel glycopeptide PKX‐001

    by Ishaq A. Viringipurampeer, Anat Yanai, Vahitha S. Nizamudheen, Cheryl Y. Gregory‐Evans, Kevin Gregory‐Evans

    Cell replacement therapy is emerging as an important approach in novel treatments for neurodegenerative diseases. Many problems remain, in particular improvements are needed in the survival of transplanted cells and increasing functional integration into host tissue. These problems arise because of immune rejection, suboptimal precursor cell type, trauma during cell transplantation, toxic compounds released by dying tissues and nutritional deficiencies. We recently developed an ex vivo system to facilitate identification of factors contributing to the death of transplanted neuronal (photoreceptor) and showed 2.8‐fold improvement in transplant cell survival after pre‐treatment with a novel glycopeptide (PKX‐001). In this study we extended these studies to look at cell survival, maturation and functional integration in an in vivo rat model of rhodopsin‐mutant retinitis pigmentosa causing blindness. We found that only when human photoreceptor precursor cells (PPCs) were pre‐incubated with PKX‐001 prior to transplantation, did the cells integrate and mature into cone photoreceptors expressing S‐opsin or L/M opsin. In addition, ribbon synapses were observed in the transplanted cells suggesting they were making synaptic connections with the host tissue. Furthermore, optokinetic tracking and electroretinography responses in vivo were significantly improved compared to cell transplants without PKX‐001 pre‐treatment. These data demonstrate that PKX‐001 promotes significant long‐term stem cell survival in vivo, providing a platform for further investigation towards the clinical application to repair damaged or diseased retina.


  • Open Access

    Photoreceptor precursor cell integration into rodent retina after treatment with novel glycopeptide PKX-001

    by Ishaq A. Viringipurampeer, Anat Yanai, Cheryl Y. Gregory-Evans, Kevin Gregory-Evans

    SUMMARY: Cell replacement therapy is emerging as an important approach in novel treatments for neurodegenerative diseases. Many problems remain, in particular improvements are needed in the survival of transplanted cells and increasing functional integration into host tissue. These problems arise because of immune rejection, suboptimal precursor cell type, trauma during cell transplantation, toxic compounds released by dying tissues and nutritional deficiencies. We recently developed an ex vivo system to facilitate identification of factors contributing to the death of transplanted neuronal (photoreceptor) and showed 2.8-fold improvement in transplant cell survival after pre-treatment with a novel glycopeptide (PKC-100). In this study we extended these studies to look at cell survival, maturation and functional integration in an in vivo rat model of rhodopsin-mutant retinitis pigmentosa causing blindness. We found that only when human photoreceptor precursor cells (PPCs) were pre-incubated with PKX-100 prior to transplantation, did the cells integrate and mature into cone photoreceptors expressing S-opsin or L/M opsin. In addition, ribbon synapses were observed in the transplanted cells suggesting they were making synaptic connections with the host tissue. Furthermore, optokinetic tracking and electroretinography responses in vivo were significantly improved compared to cell transplants without PKX-100 pre-treatment. These data demonstrate that PKX-100 promotes significant long-term stem cell survival in vivo , providing a platform for further investigation towards the clinical application to repair damaged or diseased retina.


  • An update on the genetics of ocular coloboma

    by Aisha S. Alsomiry, Cheryl Y. Gregory-Evans, Kevin Gregory-Evans

    Ocular coloboma is an uncommon, but often severe, sight-threatening condition that can be identified from birth. This congenital anomaly is thought to be caused by maldevelopment of optic fissure closure during early eye morphogenesis. It has been causally linked to both inherited (genetic) and environmental influences. In particular, as a consequence of work to identify genetic causes of coloboma, new molecular pathways that control optic fissure closure have now been identified. Many more regulatory mechanisms still await better understanding to inform on the development of potential therapies for patients with this malformation. This review provides an update of known coloboma genes, the pathways they influence and how best to manage the condition. In the age of precision medicine, determining the underlying genetic cause in any given patient is of high importance.


  • Retinal therapy with induced pluripotent stem cells; leading the way to human clinical trials

    by Anat Yanai, Pia McNab, Kevin Gregory-Evans

    Introduction: Retinal cell transplantation is a promising approach to delay progression and reverse blindness caused by infections, genetic inheritance, or associated with aging. Areas covered: The demand for transplantable retinal cells is broad and several cell sources exist that can supply such cells. The recent development of protocols that reprogram adult cells to their pluripotent potential (induced pluripotent stem cells; iPSCs) and the possibility of differentiating iPSCs to many retinal types make these cells very attractive for cell therapeutics in the degenerating retina.iPSCs overcome ethical dilemmas in using fetal cells and with autologous transplantation of iPSC derived retinal cells, immunosuppression will no longer be needed. Importantly, gene editing of iPSCs derived from patients with genetic diseases will allow autologous transplantation of healthy differentiated retinal cells. Expert commentary: Before marketing clinically useful retinal cells, differentiated from iPSCs, a multistep clinical trial is performed. Currently, 23 trials are described in the literature and they report no adverse reactions to cell transplantation. Early visual assessment tests demonstrate small visual benefits in a proportion of participants, with future results anticipated in the near future.